The data used in the current study were derived from a deidentified National Cancer Data Base file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used or the conclusions drawn from these data by the investigators.
The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base
Version of Record online: 15 APR 2014
© 2014 American Cancer Society
Volume 120, Issue 14, pages 2114–2121, 15 July 2014
How to Cite
Martin, J. M., Handorf, E. A., Kutikov, A., Uzzo, R. G., Bekelman, J. E., Horwitz, E. M. and Smaldone, M. C. (2014), The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer, 120: 2114–2121. doi: 10.1002/cncr.28697
The interpretation and reporting of these data are the sole responsibility of the authors.
- Issue online: 1 JUL 2014
- Version of Record online: 15 APR 2014
- Manuscript Revised: 4 MAR 2014
- Manuscript Accepted: 4 MAR 2014
- Manuscript Received: 12 FEB 2014
- 9National Comprehensive Cancer Network. Prostate Cancer V1. 2014 http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed on March 20, 2014.
- 20Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109(suppl 1):22-29., , , et al.